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ABSTRACT: Derivatives of the amino acid tryptophan (Trp) serve
as precursors for the chemical and biological synthesis of complex
molecules with a wide range of biological properties. Trp analogues
are also valuable as building blocks for medicinal chemistry and as
tools for chemical biology. While the enantioselective synthesis of Trp
analogues is often lengthy and requires the use of protecting groups,
enzymes have the potential to synthesize such products in fewer steps
and with the pristine chemo- and stereoselectivity that is a hallmark of
biocatalysis. The enzyme TrpB is especially attractive because it can
form Trp analogues directly from serine (Ser) and the corresponding
indole analogue. However, many potentially useful substrates,
including bulky or electron-deﬁcient indoles, are poorly accepted.
We have applied directed evolution to TrpB from Pyrococcus furiosus and Thermotoga maritima to generate a suite of catalysts for
the synthesis of previously intractable Trp analogues. For the most challenging substrates, such as nitroindoles, the key to
improving activity lay in the mutation of a universally conserved and mechanistically important residue, E104. The new catalysts
express at high levels (>200 mg/L of Escherichia coli culture) and can be puriﬁed by heat treatment; they can operate up to 75 °C
(where solubility is enhanced) and can synthesize enantiopure Trp analogues substituted at the 4-, 5-, 6-, and 7-positions, using
Ser and readily available indole analogues as starting materials. Spectroscopic analysis shows that many of the activating
mutations suppress the decomposition of the active electrophilic intermediate, an amino-acrylate, which aids in unlocking the
synthetic potential of TrpB.
■ INTRODUCTION
To develop functional complex molecules, synthetic chemists
must have access to a broad range of chemical building blocks.
These include noncanonical amino acids, which are not found
in proteins, but are often encountered as intermediates in
biosynthesis. Derivatives of tryptophan (Trp) occupy a
distinguished position in the echelons of noncanonical amino
acids, because they are biosynthetic precursors to compounds
that possess diverse activities,1,2 including anticancer, antibiotic,
immunosuppressant, antifungal, and phytotoxic properties.
Tryptophan analogues have also been used as starting materials
for chemical syntheses3−9 as well as probes for chemical
biology.10−13 Therefore, eﬃcient methods to synthesize Trp
analogues are needed.
Enzymes have emerged as powerful new tools for chemical
synthesis, catalyzing reactions with unrivaled rate acceleration
and exceptional selectivity.14−16 While nature has created a vast
repertoire of enzymes that modify Trp through a plethora of
transformations, including nitration, halogenation, and alkyla-
tion (Figure 1a),2 only a few of these enzymes have been
investigated for use in synthetic chemistry.17−22 Furthermore,
this approach is limited because the synthesis of each Trp
analogue requires a diﬀerent enzyme. We wished to develop an
alternate biocatalytic approach, in which a single catalyst
platform would provide direct access to any Trp analogue from
readily available starting materials.
Enzymes such as acylases9,23 and transaminases24 (Figure 1b)
have been applied to synthesis of Trp analogues, but in these
approaches, the majority of the product must be assembled in
advance, with the enzymes mostly serving to set the
stereochemistry at the end. Many methods, such as those
that use esterases, rely on kinetic resolution, which limits the
maximum theoretical yield of product to 50%. A notable
exception is the use of tryptophan synthase (TrpS), which can
assemble Trp analogues from L-serine (Ser) and the
corresponding indole analogue with retention of enantiopurity
(Figure 1c).25−30
While the chemical synthesis of Trp analogues is challenging,
methods to prepare indole analogues abound.31,32 Thus, the
TrpS methodology has the potential to provide direct access to
a wide array of products. Unfortunately, the activity of wild-type
TrpS is highly sensitive to the electronic and steric properties of
the substrates. Protein-engineering techniques such as directed
evolution are an eﬀective means to unlock new function, such
as high activity with non-native substrates. However, directed
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evolution has scarcely been applied to TrpS, partly because this
protein is a complex of two distinct proteins: an α-subunit
(TrpA) and a β-subunit (TrpB). Although only TrpB is
involved in the proposed synthesis of Trp analogues, TrpA is an
allosteric actuator, whose absence severely attenuates TrpB
activity. Recently, we developed variants of TrpB from
Pyrococcus furiosus33,34 and other organisms,35 which do not
require their TrpA partner proteins to achieve full activity. We
therefore wished to expand this initial set of stand-alone
variants into a general platform for the synthesis of Trp
analogues, especially those on which TrpS is poorly active.
In an initial survey of substrates, our attention was
immediately drawn to 4-substituted indoles, since this
substitution pattern is present in natural products, but was
poorly reactive in previous studies with TrpB. In particular, we
focused on 4-nitroindole (Scheme 1) because the nitro
substituent not only creates a steric impediment to substrate
binding, but also withdraws electron density from the indole
moiety. Since the indole is a nucleophile in this reaction
manifold, electron-withdrawing substituents are intrinsically
deactivating. The compound 4-nitrotryptophan (4-nitroTrp) is
a biosynthetic and chemical precursor to thaxtomin A, a
potentially useful agrochemical (Chart 1).4,36−38 Additionally,
4-nitroTrp is a chemical precursor to the tumor-promoter
indolactam V.5 However, the chemical synthesis of enantiopure
4-nitroTrp is complex,4 and the natural enzymatic route is not
amenable to application on a large scale.39 Furthermore, we
hypothesized that the evolutionary journey toward an
optimized TrpB catalyst for 4-nitroTrp would yield catalysts
with improvements for other challenging substrates.
■ RESULTS
Initial Activity of Stand-Alone Variants toward 4-
Nitroindole. TrpB enzymes from P. furiosus and Thermotoga
maritima are optimal parents for directed evolution, due to their
high thermostability.40 We therefore tested the wild-type
proteins (PfTrpB and TmTrpB), as well as the already-
generated stand-alone variants for the production of 4-nitroTrp.
As expected, the wild-type enzymes exhibited only trace activity
(Figure S1). In addition, many of the variants formed a
signiﬁcant amount of a side product, which is putatively
isotryptophan 1 (Figure 2). Fortunately, one variant, Pf 2B9,
provided 18% conversion of 4-nitroindole to 4-nitroTrp.
Notably, this variant, which has eight mutations from wild-
type PfTrpB, was initially evolved for activity with indole and
threonine (Thr).34 Thus, the fortuitous improvement for 4-
nitroindole and Ser lent support to our hypothesis that
optimizing a catalyst for production of 4-nitroTrp would
provide simultaneous gains for other substrates.
We looked to the TrpB catalytic mechanism in order to
identify what might be limiting conversion of 4-nitroindole.
TrpB uses the cofactor pyridoxal phosphate (PLP), which is
covalently bound to a lysine residue in the active site (Figure
2a, intermediate I). The lysine is displaced by Ser (intermediate
II), which then undergoes α-deprotonation (intermediate III)
and β-elimination to generate the active electrophile, amino-
acrylate IV. Ideally, this would be attacked by the nucleophilic
substrate, such as 4-nitroindole, to form the Trp product.
We observed that increasing catalyst loading had a negligible
eﬀect on production of 4-nitroTrp (Figure S2a), but that the
Ser was almost completely consumed at the end of the reaction
Figure 1. Synthesis of Trp analogues. (a) Examples of biosynthetic
intermediates derived from Trp. (b) Previous synthetic methods using
enzymes.9,23,24 (c) Alternative biocatalytic route based on TrpB. Ac =
acetyl.
Scheme 1. Test Reaction for Optimization of TrpB
Chart 1. Natural Products Synthesized from 4-NitroTrp
Figure 2. Putative pathways for reaction with 4-nitroindole. (a)
Catalytic cycle for formation of 4-nitroTrp. (b) Enzymatic
decomposition of Ser. (c) Competitive formation of isotryptophan 1.
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period (Figure S3). By contrast, production of 4-nitroTrp was
improved by addition of excess Ser (Figure S2b). These
observations are consistent with the well-known side reaction in
which the amino-acrylate is ejected from the PLP cofactor and
undergoes hydrolytic decomposition to pyruvate (Figure 2b).41
In addition, we sometimes observed formation of what we
believe is isotryptophan 1 (Figure 2c and Figure S4a), in which
4-nitroindole adds to the amino-acrylate through the endocyclic
nitrogen atom (N1) rather than the desired carbon atom (C3).
While this reaction appears to be reversible, it undoubtedly
slows the desired reaction. Our goal was to engineer a TrpB
that would rapidly and quantitatively convert equimolar
amounts of 4-nitroindole and Ser into 4-nitroTrp with perfect
regio- and enantioselectivity.
Eﬀects of Active-Site Mutagenesis. Lacking a high-
throughput assay for production of 4-nitroTrp, we initially
focused on small site-saturation mutagenesis libraries that could
be screened by high-performance liquid chromatography
(HPLC). Previously, an X-ray crystal structure was obtained
of TrpB from Salmonella enterica (SeTrpB) with both the
amino-acrylate and benzimidazole, an indole mimic, bound in
the active site (PDB ID: 4HPX).42 Although PfTrpB and
SeTrpB have modest sequence identity (59%), we previously
observed a high degree of structural similarity between
structures of PfTrpB and TrpB from Salmonella typhimurium
(StTrpB), which also have only 59% sequence identity.33 We
therefore constructed a homology model with the sequence of
PfTrpB and placed 4-nitroindole into the binding pose
necessary to achieve C−C bond formation, in the hope of
identifying steric clashes that could be alleviated by mutations
(Figure 3). Unfortunately, the model suggested that the nitro
group was clashing with the protein main chain as well as with
the PLP cofactor (Figure 3a). Nonetheless, we identiﬁed four
residues whose side chains extended into the indole-binding
pocket: L161, I165, V187, and Y301 (Figure 3b). The side
chain of E104 also occupies the active site, but this residue is
thought to bind indole through the NH moiety, thereby
promoting attack from C3. Since this residue is universally
conserved in TrpB homologues, and the enzymes already
suﬀered from poor regioselectivity with 4-nitroindole, we
elected to avoid mutagenesis at this position. We hypothesized
that mutation at the other four positions could create space for
4-nitroindole to bind in an alternative pose that relieved the
steric clashes but still allowed for attack of the amino-acrylate.
Mutations of the targeted residues were almost uniformly
deleterious, with the exception of L161V, which boosted the
yield of 4-nitroTrp to 25%. While this improvement is modest,
the mutation also suppressed formation of the side-product
(Figure S4b). It is worth noting that although the side-chain of
valine is indeed smaller than that of leucine, mutation of this
position to alanine is deleterious. Thus, the eﬀects of active-site
mutagenesis cannot be rationalized by simple models based on
sterics.
Screening of random-mutagenesis libraries. Having
failed to achieve signiﬁcant gains in activity from active-site
mutagenesis, we hoped that random mutagenesis would
provide beneﬁcial mutations elsewhere in the protein scaﬀold.
However, such libraries often have low frequencies of beneﬁcial
mutations, the result of which is that large numbers (hundreds
to thousands) of variants must be screened to ﬁnd improve-
ments. In our initial generation of the stand-alone TrpB
catalysts, we had exploited the spectroscopic shift between
indole and Trp to screen initial rates in a high-throughput
manner.33 However, 4-nitroindole proved to be substantially
more diﬃcult. Unlike indole, 4-nitroindole has minimal
solubility in water, even with 5% dimethyl sulfoxide (DMSO)
as a co-solvent. Furthermore, the initial rate of even the most
evolved catalyst was too low to screen reliably, a problem
compounded by the fact that the spectral diﬀerence between 4-
nitroindole and 4-nitroTrp is much smaller than that of indole
and Trp. Instead, we chose to exploit the solubility diﬀerences
between 4-nitroindole and 4-nitroTrp. Speciﬁcally, the
reactions were run in aqueous conditions with 5% DMSO as
a co-solvent, then the residual starting material was extracted in
an organic solvent (ethyl acetate). The amount of 4-nitroTrp
was determined by measuring the absorption of the aqueous
phase in the visible spectrum.
Using the newly developed assay, we tested a random-
mutagenesis library, generated by error-prone polymerase chain
reaction, and identiﬁed a variant, with mutations M139L and
L212P, that almost doubled the HPLC yield of 4-nitroTrp to
49% (Figure 4). We next tested a library which randomly
recombined those two mutations and N166D, a beneﬁcial
mutation identiﬁed in a separate study.35 We also varied the
active-site L161V mutation, since its eﬀect had been
comparatively minor. Indeed, in the best variant from this
library (Pf5G8), the active-site mutation had reverted back to
leucine and the other three mutations were retained. This
variant formed 4-nitroTrp in 60% HPLC yield from equimolar
amounts of 4-nitroindole and Ser.
Figure 3. Model of 4-nitroindole (yellow) and the amino-acrylate in
the active site of PfTrpB (see Section 8.13 of Supporting
Information). (a) Nitro group clashes with the protein backbone
(green) and the PLP cofactor (purple). (b) Alternative view showing
side-chains extending in to the active site and hydrogen bond with
E104.
Figure 4. Evolutionary progression in production of 4-nitroTrp.
Mutations in bold were added in the corresponding round of
mutagenesis and screening. Dashed lines denote a new round of
random mutagenesis. The horizontal axis indicates catalyst desig-
nations. See Section 8.7 of the Supporting Information for
experimental details.
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Energized by that success, we generated another random-
mutagenesis library with Pf5G8 as the parent protein. From this
library, two mutations were found (I183F and V186A) that
increased HPLC yield slightly, to ∼70%. The most signiﬁcant
improvement, however, came from a variant bearing the
mutation E104G, which increased HPLC yield to ∼86% and
eviscerated the earlier supposition that an H-bonding
interaction with 4-nitroindole and the side-chain of E104
would promote the reaction. We then screened a recombina-
tion library and found that the E104G mutation recombined
with I183F and V186A to produce 4-nitroTrp in 91% HPLC
yield. Finally, we screened a site-saturation library at position
104 and found that glycine at this position was optimal, with
Ala yielding similar, but slightly inferior results (Figure S5).
Optimization toward Isomeric Nitroindoles. With the
new catalysts in hand, we wished to see if the evolution had
created speciﬁcity for 4-nitroindole, or if it had improved
activity for other substrates as well. We therefore tested
catalysts Pf5G8 and Pf 2A6 with 5-, 6-, and 7-nitroindole (Chart
2). Gratifyingly, Pf5G8 showed improvement for all substrates
compared to Pf 2B9, forming all isomeric nitrotryptophans in
about 60% HPLC yield (Table 1, entries 1 and 2). Enzyme
Pf 2A6, on the other hand, showed almost quantitative
conversion of 7-nitroindole to the corresponding nitroTrp,
but low activity with 5- and 6-nitroindole (Table 1, entry 3).
Because we had previously identiﬁed catalysts that exhibited
moderate activity with these substrates, we wondered if a subset
of the mutations from Pf 2A6 would further activate them for 5-
and 6-nitroindole. The mutations associated with each catalyst
designation are summarized in Table 2.
Previously, engineered variants of TmTrpB had shown higher
activity with 5-substituted indoles than their PfTrpB homo-
logues.35 Additionally, it was observed that if certain beneﬁcial
mutations in PfTrpB variants were transferred to the
corresponding positions in TmTrpB, then the activating eﬀects
were also transferred.35 We therefore constructed a library in
which the mutations of Pf 2A6 were randomly recombined at
the corresponding positions in TmTrpB. Screening for activity
with 5-nitroindole revealed two variants that outperformed all
previous catalysts in the production of 5-nitrotryptophan (5-
nitroTrp). The ﬁrst, Tm2F3, contained ﬁve mutations that were
originally found in Pf 2B9 plus all three mutations from Pf5G8;
this variant formed 5-nitroTrp in 76% HPLC yield (Table 1,
entry 4). The second variant was identical, but also contained
one of the mutations found in Pf 2A6 (I184F, according to
numbering in T. maritima). This mutation gave a further boost
in yield to 86% (Table 1, entry 5).
To improve activity with 6-nitroindole, we returned to the
parent enzyme Pf 2B9 and the active-site mutagenesis libraries
from the beginning of this study. Although these libraries had
not yielded signiﬁcant gains for 4-nitroindole, we hypothesized
that 6-nitroindole might respond diﬀerently, due to its distinct
shape. Indeed, while no mutation at L161 was activating, the
single mutations I165F and Y301H were both beneﬁcial
(Figure S6). Ultimately, the best variant contained both of
these mutations and formed 6-nitroTrp in 66% HPLC yield
(Table 1, entry 6). A random recombination library of the
mutations from Pf 2A6 revealed a new variant, Pf 0A9, bearing
mutations M139L and N166D, which increased the yield to
86% (Table 1, entry 7). Surprisingly, the mutation E104G also
enhanced activity, albeit modestly, to 91% yield (Table 1, entry
8).
Substrate Scope of Catalyst Panel. To evaluate their
generality and synthetic utility, we tested the newly optimized
catalysts against a range of indole substrates (Table 3). We
were pleased to ﬁnd that the catalysts accepted essentially every
indole analogue that we tested, often forming the correspond-
ing Trp product in excellent yield. For preparative reactions,
however, we chose to focus on halogenated and electron-
deﬁcient indoles, since historically these have been the most
challenging.
Despite the tremendous improvement in 4-nitroTrp
production, the catalysts still struggled with substituents at
the 4-position. With 4-nitroindole, Pf 2A6 can achieve ∼5000
turnovers, but the reaction seems to slow considerably toward
the end (Figure S7). As a result, a higher catalyst loading is
required to achieve the high conversion observed in the catalyst
evolution (Table 3, entry 1). Fortunately, the catalysts are
expressed at high levels (>200 mg/L of E. coli culture) and can
be used as heat-treated lysate, without additional protein
puriﬁcation. As a result, we were easily able to synthesize over a
gram of 4-nitroTrp (73% isolated yield) using the protein from
a 1-L bacterial culture (see Section 9.4 of Supporting
Information). The enzymes could also form 4-ﬂuorotryptophan
in excellent yield (Table 3, entry 2), as well as 4-bromo- and 4-
cyanotryptophan, albeit with modest activity (Table 3, entries 3
and 4, respectively). With indole-4-boronic acid, however, no
product was detected (Table 3, entry 5). Strangely, the optimal
Chart 2. Nitro Substitution at Other Positions
Table 1. Optimizing Catalysts for Other Nitroindole Isomers
HPLC yield of nitroTrp (%)b
entry catalysta 4-nitro 5-nitro 6-nitro 7-nitro
1 Pf 2B9 18 8 17 29
2 Pf5G8 60 64 64 64
3 Pf 2A6 91 5 26 >99
4 Tm2F3 76
5 Tm2F3 I184F 86
6 Pf 2B9 I165F Y301H 66
7 Pf 0A9 86
8 Pf 0A9 E104G 91
aSee Table 2 for catalyst designations. bReactions used equimolar
amounts of nitroindole and Ser. See Section 8.7 of the Supporting
Information for experimental details.
Table 2. Catalyst Designations and Associated Mutations
designation
species of
origin mutations
Pf 2B9a P. furiosus I16V, E17G, I68V, F95L, T292S, F274S, T321A,
V384A
Pf5G8 P. furiosus Pf 2B9 + M139L, N166D, L212P
Pf 2A6 P. furiosus Pf5G8 + E104G
Pf 0A9 P. furiosus Pf 2B9 + M139L, I165F, N166D, Y301H
Tm2F3 T. maritima P19G, I69V, K96L, P140L, N167D, L213P,
T292S
aVariant from ref 34.
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catalyst was diﬀerent for almost every substrate, further
underscoring the idiosyncrasy of 4-substitution.
As with 4-nitroindole, the reaction with 5-nitroindole slowed
toward the end (Figure S8). Nonetheless, 5-nitroTrp could be
obtained in 88% yield with a higher catalyst loading (Table 3,
entry 6). Good results were also obtained with other electron-
withdrawing substituents, such as nitrile, carboxamide, and
boronate (Table 3, entries 7−9). Notably, we also observed
promising activity with 5-iodo- and 5-triﬂuoromethylindole
(Table 3, entries 10 and 11), on which previous catalysts had
shown no detectable activity.
The 6-substituted indoles proved to be the best behaved and
most predictable series of substrates. At this position, high
yields were obtained with the nitro substituent (Table 3, entry
12), as well as halo substituents (Table 3, entries 13 and 14)
and other electron-withdrawing substituents like nitrile (Table
3, entry 15) and boronate (Table 3, entry 16). Unlike with the
4- and 5-positions, the two enzymes evolved for activity with 6-
nitroindole were always among the best catalysts.
Excellent activity was also observed with 7-substituted
indoles, though the optimal catalyst was hard to predict.
While 7-nitroindole and 7-cyanoindole favored Pf 2A6 (Table 3,
entries 17 and 18), Pf 0A9 gave optimal activity for 7-chloro-
and 7-iodoindole (Table 3, entries 19 and 20). Strangely, 7-
bromoindole gave poorer results than the other haloindoles,
though 7-bromotryptophan could be formed in modest yield
with catalyst Pf5G8 (Table 3, entry 21). No product was
detected with indole-7-boronic acid (Table 3, entry 22).
Finally, we explored the production of Trp analogues with
multiple substituents. This capability is important both because
poly-substituted Trp derivatives are precursors to many natural
products and because poly-halogenated arenes are prevalent in
bioactive compounds in general.22,43 Fortunately, the 5,6-
dichloro and 5-bromo-7-ﬂuoro products could be obtained in
good yields using Pf5G8 and Tm2F3 I184F, respectively (Table
3, entries 23 and 24). The bulkier 5-chloro-7-iodo product was
also accessible, though in low yield (Table 3, entry 25).
Kinetic Eﬀects of the Mutations. Our hypothesis at the
outset of this project had been that the conversion of slowly
reacting substrates like 4-nitroindole was limited by competing
hydrolysis of the amino-acrylate intermediate. Increasing the
conversion at the reaction end point, therefore, would require
accelerating the nucleophilic attack of the substrate, such as
through binding in the active site, and increasing the
persistence of the amino-acrylate intermediate. While the
poor solubility of 4-nitroindole frustrated our ability to measure
Michaelis−Menten kinetics, we could approximate the initial
rate of 4-nitroTrp production under the reaction conditions by
measuring conversion at short reaction times (Table 4). In
addition, we measured the rate of Ser deamination by
incubating the enzymes with Ser, in the absence of a
nucleophilic substrate, and measuring the production of
pyruvate. Finally, we measured the initial rate of Trp
production under the same reaction conditions that we used
for 4-nitroTrp.
Table 3. Tryptophan Analogues Produced by Catalyst Panela
aReactions used 0.02 mol % catalyst loading (maximum 5000 turnovers) and 1.1 equiv Ser relative to indole substrate. bCatalyst loading was 0.1 mol
% (maximum 1000 turnovers). cReaction gives alkylation at nitrogen. ND, not detected.
Table 4. Initial Rates Throughout Evolutiona
initial turnover frequency (min−1)
entry catalyst to 4-nitroTrp to pyruvate to Trp
1 PfTrpB − 25.0 ± 0.3 19 ± 1.2
2 Pf 2B9 1.25 ± 0.07 12.2 ± 0.5 60.9 ± 0.16
3 Pf5G8 1.8 ± 0.12 2.0 ± 0.2 9.9 ± 0.5
4 Pf5G8 E104G 3.5 ± 0.2 0.9 ± 0.12 7.03 ± 0.07
5 Pf 2A6 7.0 ± 0.3 1.4 ± 0.10 17.6 ± 0.3
aSee Sections 8.10, 8.11, and 8.12 of the Supporting Information.
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Of all the catalysts, wild-type TrpB has the highest
deamination rate, even higher than the rate of Trp production,
and produces negligible levels of 4-nitroTrp (Table 4, entry 1).
The variant Pf 2B9, which produces Trp at a rate similar to the
wild-type complex,33 shows both an increase in the rate of 4-
nitroTrp production and a decrease in the rate of Ser
deamination (Table 4, entry 2). The next variant, Pf5G8,
exhibits only a modest increase in the rate of 4-nitroTrp
production, but a 6-fold decrease in the rate of Ser deamination
and an almost 3-fold decrease in the rate of Trp production
(Table 4, entry 3). The mutation E104G changes both 4-
nitroTrp production and Ser deamination in approximately
equal measure, but surprisingly exerts only a minor inﬂuence on
Trp production (Table 4, entry 4). Finally, the addition of
I183F and V186A actually increases the rate of Ser
deamination, but increases the rate of the desired reaction
even more (Table 4, entry 5). These last two mutations also
return Trp production to the level of PfTrpB.
■ DISCUSSION
Organic Synthesis Using TrpB. In the synthesis of
noncanonical amino acids, installation of the chiral amino-
acid moiety is often the most challenging part, due to the
stereochemistry at the α-carbon. Many synthetic approaches,
therefore, involve the modiﬁcation of existing amino acids, in
which the stereochemistry is already established. Even then, the
reactivity of the amine and carboxylate functional groups can
interfere with many synthetic methodologies, and thus require
protecting groups. In contrast, TrpB uses unprotected Ser as
the amino acid donor and forms the products in almost perfect
enantiopurity. The reaction is operationally straightforward
(simply add substrates and enzyme to buﬀer and apply heat),
and the products can often be puriﬁed by precipitation directly
from the reaction mixture, or alternatively by a facile
chromatographic separation. Due to their high expression
level and thermostability, the enzymes can be obtained easily
and handled without special precautions. Furthermore, the
active electrophilic species, the amino-acrylate, is formed and
persists only in the enzyme active site, thus minimizing the
burden of product puriﬁcation.
While the range of products formed by TrpB was previously
restricted to a narrow set of Trp analogues, the results of this
study demonstrate that the product scope can be greatly
expanded through protein engineering. More generally, they
show how TrpB can mediate eﬃcient reactions with excep-
tionally weak nucleophiles like 4-nitroindole, which is electroni-
cally deactivated, sterically hindered, and poorly soluble. It is
likely, therefore, that the product scope of TrpB can be
expanded even further to include many types of noncanonical
amino acids, in addition to Trp analogues.
Role of M139 and N166 in Open/Close Transition.
TrpB is well known to adopt discrete conformational states,
including a fully open state, which is inactive but permits
substrate entry and product release, and a fully closed state,
which promotes amino-acrylate formation and nucleophilic
addition but blocks access to the active site. Previous studies
have also shown that stabilization of the closed state is
associated with a decreased rate of Ser deamination.44 Since
M139L and N166D lie outside the active site, we hypothesized
that their beneﬁcial eﬀect, which is mainly to suppress Ser
deamination, might arise from stabilization of the closed state.
While the evolved variants from this study did not form
diﬀracting crystals, we previously obtained structures of wild-
type PfTrpB in the open and partially closed states.33 A
comparison of the structures immediately reveals that the side-
chain of N166, which is mutated to aspartate in Pf5G8, forms a
hydrogen bond in the closed state with the side-chain of H275,
which undergoes a rotameric switch that closes the active site
(Figure 5). It is therefore plausible that strengthening of this
interaction with the more basic aspartate would stabilize the
closed state of the enzyme. Interestingly, the parent enzyme,
Pf 2B9, also has the mutation F274S, which is adjacent to H275,
thus highlighting the importance of mutations in this region to
activity. The eﬀect of mutating M139 to L is more diﬃcult to
rationalize, but this residue is adjacent to the domain that
mediates communication between TrpA and TrpB in the wild-
type complex and which is known to undergo a large
displacement in the transition from open to closed. Thus, it
is plausible that a mutation at this position would inﬂuence the
transition between the open and closed states.
Inﬂuence of Mutations on the Active Site. Unlike the
previous stages of evolution, all the mutations from the ﬁnal
round (E104G, I183F, and V186A) occur at positions in the
enzyme active site. In the case of I183 and V186, the side-
chains do not interact directly with the substrates, nor do they
undergo signiﬁcant movement during the transition from the
open to closed state. Thus, the beneﬁcial eﬀects of the
mutations are likely due to subtle reshaping of the active site to
accommodate the size of 4-nitroindole and bind the substrate in
a more reactive conformation. This is consistent with the
observation that addition of these two mutations greatly
increases the rate of 4-nitroTrp production while exerting little
eﬀect on the rate of Ser deamination (Table 4, entries 4 and 5).
Various roles have been assigned to the side-chain of E104,
including activation of the Ser β-hydroxyl group as a leaving
group, as well as binding and activation of the indole
nucleophile (see Figure 2, intermediates II and III).45 Indeed,
studies of TrpS from S. typhimurium (StTrpS) showed that
mutation of the corresponding residue to alanine46 eliminated
activity with indole and Ser.47 However, this activity was
rescued by the introduction of certain monovalent cations, such
as Cs+, indicating that neither of the aforementioned roles of
E104 are essential. It therefore seems that its most signiﬁcant
role is in modulating the transition of the enzyme to the closed
state. This was supported by the observation that increasing
concentrations of CsCl shifted the catalytic steady state of the
variant away from the external aldimine (Figure 2, intermediate
II) toward the amino-acrylate as the major species, a trend that
is a hallmark of closed-state stabilization. By contrast, Pf5G8
and the E104G variants exhibit similar rates of Trp production,
and the amino-acrylate predominates in the steady state of both
variants (Figure S9). In fact, the E104G mutation appears to
stabilize the closed state, as inferred from the 2-fold decrease in
Figure 5. Overlaid crystal structures of PfTrpB (PDB ID: 5DVZ) in
the open state (cyan) and partially closed state (PDB ID: 5DW0, red)
showing the side-chain motion of N166, and H275.
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deamination rate (Table 4, entries 3 and 4). Thus, it may be
that the other mutations in Pf5G8 have changed the function of
E104, or that the role of this residue is diﬀerent in PfTrpB and
StTrpB. Studies are ongoing to elucidate the role and generality
of this mysterious mutation.
Impact on Substrate Speciﬁcity. It is often thought that
evolving an enzyme for activity with a particular substrate
ultimately imparts speciﬁcity toward that substrate as well. This
study, however, shows that directed evolution toward a
particularly challenging substrate can be an eﬀective strategy
to improve activity for non-native substrates in general. Indeed,
the intermediate catalyst, Pf5G8, exhibited concomitant
increases in activity for all four nitroindoles (Table 1). While
this enzyme was rarely the optimal catalyst, as indicated by its
infrequent appearance in Table 3, it exhibited good activity for
most substrates (see Table S1). The additional mutations in the
most evolved enzyme, Pf 2A6, appeared to lower the substrate
generality, but nonetheless improved activity for multiple
substrates, such as 7-nitroindole, in addition to the test
substrate, 4-nitroindole. Furthermore, the mutations of Pf 2A6
served as the basis to generate all other catalysts in this study,
demonstrating that although a speciﬁc catalyst may not be
optimal for all substrates, the mutations are activating in
multiple contexts.
Our approach of creating a small panel of general catalysts
likely succeeded because the conversion of most non-native
substrates was limited by a single enzymatic process, Ser
hydrolysis. Thus, directed evolution could select for mutations
that curtailed Ser hydrolysis independently of a speciﬁc
substrate. This is consistent with the results of Table 4, in
which the rate of Ser deamination decreases even in the
absence of a nucleophilic substrate. While these speciﬁc
circumstances may not apply to all enzyme engineering
problems, we would expect directed evolution to provide a
general beneﬁt where side activities that limit enzyme
performance can be targeted independently.
■ CONCLUSION
By evolving for activity with nitroindoles, we have developed a
panel of TrpB-derived biocatalysts that exhibit good to
excellent activity with mono- and disubstituted indoles. The
substrate scope includes indoles bearing electron-withdrawing
groups, such as nitro and cyano, which are fundamentally
deactivating in this reaction manifold. These results showcase
the potency of the amino-acrylate as an electrophile, as well as
the ability of the active site to protect the amino-acrylate from
degradation, while promoting reactions with even the most
stubborn nucleophiles. These qualities make TrpB catalysis a
versatile and easy-to-use platform for the production of valuable
synthetic building blocks.
The results also demonstrate that the universally conserved
E104 residue is a key target for mutagenesis to improve activity
with non-native substrates. This may provide a promising
starting point to adapt TrpB for the synthesis of new product
classes. More generally, this demonstrates how mutations at
residues that seem crucial can in fact be the most valuable
handles for tuning activity with new substrates.
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